GSK working toward Ebola vaccine by end of 2014

LONDON — GlaxoSmithKline expects to have its Ebola vaccine available by year's end, CEO and executive director Andew Witty told analysts during the company's third-quarter conference call Wednesday. 

 

"Given the apparent health emergency, we are leaving no stone unturned in this project," he said. "And if all goes well, I fully expect GSK to be the first company in a position to make a vaccine available to health agencies and governments hopefully, toward the end of 2014."

 

Both GSK and Johnson & Johnson are working toward providing an Ebola vaccine sooner than later. 

 

Johnson & Johnson on Wednesday announced that it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in development at its Janssen Pharmaceutical Companies. Janssen is targeting production of more than one million doses of the vaccine regimen in 2015, 250,000 of which are expected to be released for broad application in clinical trials by May 2015.